Related Experiment Video

Updated: Jan 1, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Meijun Zheng1, Jianhan Huang2, Aiping Tong3

  • 1Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, P.R. China.

Molecular Therapy Oncolytics
|December 25, 2019
PubMed

Insights

Oncolytic viruses (OVs) show promise in cancer therapy but struggle with solid tumors. Advances in viral engineering and combination strategies aim to improve their clinical efficacy for better patient outcomes.

Area of Science:

  • Oncology
  • Virology
  • Biotechnology

Background:

  • Oncolytic viruses (OVs) are emerging as potent cancer therapeutics.
  • The approval of talimogene laherparepvec (T-vec) has increased interest in OV therapy.
  • Current OV applications show limited efficacy against solid tumors.

Purpose of the Study:

  • To review the limitations and challenges of oncolytic virotherapy.
  • To describe recent advances and strategies to improve OV efficacy.
  • To summarize preclinical and clinical trials and highlight optimization needs.

Main Methods:

  • Review of recent scientific literature on oncolytic viruses.
  • Analysis of advancements in viral retargeting and genetic editing.
  • Evaluation of viral delivery platforms, tracking, gene therapy, and combination strategies.

Main Results:

  • Despite progress, significant challenges remain in treating solid tumors with OVs.
  • Novel strategies including viral retargeting, genetic engineering, and combination therapies show potential.
  • Recent trials indicate a need for optimized strategies to enhance clinical outcomes.

Conclusions:

  • Oncolytic virotherapy holds great promise but requires further optimization for solid tumors.
  • Advancements in technology and strategic combinations are key to broadening OV applications.
  • Future research should focus on refining OV strategies to improve patient treatment efficacy.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
897
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K